Search Results

There are 1808 results for: content related to: Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel

  1. Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans

    The Journal of Clinical Pharmacology

    Volume 50, Issue 2, February 2010, Pages: 126–142, Dr Nagy A. Farid, Dr Atsushi Kurihara and Dr Steven A. Wrighton

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270009343005

  2. You have full text access to this OnlineOpen article
    TRITON and Beyond: New Insights into the Profile of Prasugrel

    Cardiovascular Therapeutics

    Volume 30, Issue 4, August 2012, Pages: e174–e182, Joseph A. Jakubowski, Jeffrey S. Riesmeyer, Sandra L. Close, Amy G. Leishman and David Erlinge

    Version of Record online : 17 FEB 2011, DOI: 10.1111/j.1755-5922.2011.00263.x

  3. High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis

    Journal of Thrombosis and Haemostasis

    Volume 13, Issue 6, June 2015, Pages: 931–942, G. Lemesle, G. Schurtz, C. Bauters and M. Hamon

    Version of Record online : 21 APR 2015, DOI: 10.1111/jth.12907

  4. Integrated Analysis of Pharmacokinetic Data Across Multiple Clinical Pharmacology Studies of Prasugrel, a New Thienopyridine Antiplatelet Agent

    The Journal of Clinical Pharmacology

    Volume 51, Issue 3, March 2011, Pages: 321–332, Dr David S. Small, Ms Ying G. Li, Mr C. Steven Ernest II, Mr John H. April, Dr Nagy A. Farid, Mr Christopher D. Payne, Dr Kenneth J. Winters, Dr Shashank Rohatagi and Dr Lan Ni

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270010367429

  5. Prasugrel: A Critical Comparison with Clopidogrel

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 29, Issue 12, December 2009, Pages: 1441–1451, Dr. Kurt M. Reinhart, Dr. C. Michael White and Dr. William L. Baker

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.29.12.1441

  6. Pharmacokinetics and Pharmacodynamics of Prasugrel, a Thienopyridine P2Y12 Inhibitor

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 29, Issue 9, September 2009, Pages: 1089–1102, Dr. Paul P. Dobesh

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.29.9.1089

  7. Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel

    Journal of Clinical Pharmacy and Therapeutics

    Volume 39, Issue 6, December 2014, Pages: 663–672, W. H. Olson, Y.-W. Ma, F. Laliberté, P. Lefebvre, C. Crivera, J. R. Schein, L. E. Fields, K. Dea, G. Germain and S. M. Lynch

    Version of Record online : 23 SEP 2014, DOI: 10.1111/jcpt.12209

  8. Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 28, Issue 12, December 2008, Pages: 1483–1493, Dr. Nagy A. Farid, Dr. David S. Small, Mr. Christopher D. Payne, Dr. Joseph A. Jakubowski, Dr. John T. Brandt, Ms. Ying G. Li, Mr. C. Steven Ernest II, Dr. Daniel E. Salazar, Dr. Christopher S. Konkoy and Dr. Kenneth J. Winters

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.28.12.1483

  9. Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel

    The Journal of Clinical Pharmacology

    Volume 48, Issue 4, April 2008, Pages: 475–484, Dr David S. Small, Dr Nagy A. Farid, Mr Christopher D. Payne, Dr Govinda J. Weerakkody, Ms Ying G. Li, Dr John T. Brandt, Dr Daniel E. Salazar and Dr Kenneth J. Winters

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270008315310

  10. You have free access to this content
    Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation

    Journal of Thrombosis and Haemostasis

    Volume 11, Issue 1, January 2013, Pages: 100–106, M. U. ZAFAR, C. SANTOS-GALLEGO, D. A. VORCHHEIMER, J. F. VILES-GONZALEZ, S. ELMARIAH, C. GIANNARELLI, S. SARTORI, D. S. SMALL, J. A. JAKUBOWSKI, V. FUSTER and J. J. BADIMON

    Version of Record online : 27 JAN 2013, DOI: 10.1111/jth.12058

  11. You have free access to this content
    Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data

    Journal of Thrombosis and Haemostasis

    Volume 8, Issue 8, August 2010, Pages: 1678–1684, M. J. SORICH, A. VITRY, M. B. WARD, J. D. HOROWITZ and R. A. MCKINNON

    Version of Record online : 21 MAY 2010, DOI: 10.1111/j.1538-7836.2010.03923.x

  12. You have free access to this content
    Clinical implications of drug–drug interactions with P2Y12 receptor inhibitors

    Journal of Thrombosis and Haemostasis

    Volume 12, Issue 1, January 2014, Pages: 2–13, J. M. Siller-Matula, D. Trenk, S. Krähenbühl, A. D. Michelson and G. Delle-Karth

    Version of Record online : 9 JAN 2014, DOI: 10.1111/jth.12445

  13. Effect of grapefruit juice on the bioactivation of prasugrel

    British Journal of Clinical Pharmacology

    Volume 80, Issue 1, July 2015, Pages: 139–145, Mikko T. Holmberg, Aleksi Tornio, Hanna Hyvärinen, Mikko Neuvonen, Pertti J. Neuvonen, Janne T. Backman and Mikko Niemi

    Version of Record online : 1 JUN 2015, DOI: 10.1111/bcp.12581

  14. Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON-TIMI 38 Substudy

    The Journal of Clinical Pharmacology

    Volume 52, Issue 6, June 2012, Pages: 789–797, Dr Jeffrey S. Riesmeyer, Dr Daniel E. Salazar, Dr Govinda J. Weerakkody, Dr Lan Ni, Dr Rebecca E. Wrishko, Mr C. Steven Ernest II, Dr Junxiang Luo, Ms Ying G. Li, Dr David S. Small, Dr Shashank Rohatagi and Dr William L. Macias

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270011406280

  15. You have free access to this content
    Comparison of Prasugrel and Bivalirudin vs Clopidogrel and Heparin in Patients With ST-Segment Elevation Myocardial Infarction: Design and Rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 Trial

    Clinical Cardiology

    Volume 37, Issue 5, May 2014, Pages: 270–276, Stefanie Schulz, Gert Richardt, Karl-Ludwig Laugwitz, Roxana Mehran, Anthony H. Gershlick, Tanja Morath, Katharina Mayer, Julia Neudecker, Ralph Tölg, Tareq Ibrahim, Dieter Hauschke, Daniel Braun, Heribert Schunkert, Adnan Kastrati, Julinda Mehilli and for the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 Investigators

    Version of Record online : 14 MAR 2014, DOI: 10.1002/clc.22268

  16. Prasugrel: A Novel P2Y12 Receptor Inhibitor

    Pharmacology in the Catheterization Laboratory

    Itsik Ben-Dor, Mickey Scheinowitz, Ron Waksman, Pages: 59–66, 2009

    Published Online : 30 OCT 2009, DOI: 10.1002/9781444306347.ch9

  17. You have free access to this content
    Antiplatelet Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: A Retrospective Observational Study of Prasugrel and Clopidogrel

    Cardiovascular Therapeutics

    Volume 32, Issue 1, February 2014, Pages: 1–6, Aaron Koshy, Karthik Balasubramaniam, Awsan Noman and Azfar G. Zaman

    Version of Record online : 15 JAN 2014, DOI: 10.1111/1755-5922.12051

  18. You have free access to this content
    Prasugrel: A Novel Platelet ADP P2Y12 Receptor Antagonist

    Cardiovascular Therapeutics

    Volume 27, Issue 3, Fall 2009, Pages: 194–198, William Wilson, Ronen Gurvitch and Andrew E. Ajani

    Version of Record online : 4 AUG 2009, DOI: 10.1111/j.1755-5922.2009.00086.x

  19. A Risk–Benefit Assessment of Prasugrel, Clopidogrel, and Genotype-Guided Therapy in Patients Undergoing Percutaneous Coronary Intervention

    Clinical Pharmacology & Therapeutics

    Volume 91, Issue 5, May 2012, Pages: 829–837, G F Guzauskas, D A Hughes, S M Bradley and D L Veenstra

    Version of Record online : 28 MAR 2012, DOI: 10.1038/clpt.2011.303

  20. Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON-TIMI 38

    The Journal of Clinical Pharmacology

    Volume 49, Issue 8, August 2009, Pages: 984–998, Dr Rebecca E. Wrishko, Mr C. Steven Ernest II, Dr David S. Small, Ms Ying G. Li, Dr Govinda J. Weerakkody, Dr Jeffrey R. Riesmeyer, Dr William L. Macias, Dr Shashank Rohatagi, Dr Daniel E. Salazar, Dr Elliott M. Antman, Dr Stephen D. Wiviott, Dr Eugene Braunwald and Dr Lan Ni

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270009337942